Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes

Journal of Medicinal Chemistry

Volumn 39, Issue 26, 1996, Pages 5208-5214

  Buckley, Robert G ^a,d   Elsome, Amanda M ^a   Fricker, Simon P ^a   Henderson, Graham R ^a   Theobald, Brian R C ^a   Parish, Richard V ^b   Howe, Brian P ^b   Kelland, Lloyd R ^c  

^a JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; GOLD COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PLASMACYTOMA; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZYLAMINES; CELL DIVISION; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOGOLD COMPOUNDS; ORGANOMETALLIC COMPOUNDS; TUMOR CELLS, CULTURED;

EID: 0030477694     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9601563     Document Type: Article

References (42)

1. Parish, R. V. Gold in medicine - chrysotherapy. Interdisc. Sci. Rev. 1992, 17, 221-228.
2. Sadler, P. J. Inorganic chemistry and drug design. In Advances in Inorganic Chemistry; Sykes, A. G., Ed.; Academic Press: San Diego, 1991; Vol. 36, pp 1-48.
3. Shaw, C. F. Gold. In Metal Compounds in Cancer Therapy; Fricker, S. P., Ed.; Chapman and Hall: London, 1994; pp 46-64.
4. Ni Dhubhghaill, O. M.; Sadler, P. J. Gold complexes in cancer chemotherapy. In Metal Complexes in Cancer Chemotherapy; Keppler, B. K., Ed.; VCH: Weinheim, 1993; pp 221-248.
5. Mirabelli, C. K.; Hill, D. T.; Faucette, L. F.; McCabe, F. L.; Girade, G. R.; Bryan, D. B.; Sutton, B. M.; O'Leary Bartus, J.; Crooke, S. T.; Johnson, R. K. Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J. Med. Chem. 1987, 30, 2181-2190.
6. Berners-Price, S. J.; Mirabelli, C. K.; Johnson, R. K.; Mattern, M. R.; McCabe, F. L.; Faucette, L. F.; Sung, C.-M.; Mong, S.-M.; Sadler, P. J.; Crooke, S. T. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]-gold(I) chloride. Cancer Res. 1986, 46, 5486-5493.
7. Mirabelli, C. K.; Johnson, R. K.; Sung, C.-M.; Faucette, L. F.; Muirhead, K.; Crooke, S. T. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 1985, 45, 32-39.
8. Sadler, P. J.; Nasr, M.; Narayanan, V. L. The design of metal complexes as anticancer drugs. In Platinum Coordination Complexes in Cancer Chemotherapy; Hacker, M. P., Douple, E. B., Krakoff, I. H., Eds.; Martinus Nijhoff Publishing: Boston, 1984; pp 290-304.
9. Cattalini, L.; Orio, A.; Tobe, M. L. Nucleophilic reactivity in substitution reactions of square-planar metal complexes. II. A comparison of the kinetic behaviour of platinum(II) and gold-(III) complexes. J. Am. Chem. Soc. 1967, 89, 3130-3134.
10. Pesek, J. J.; Mason, W. R. Cyanide exchange kinetics for planar tetracyanometalate complexes by carbon-13 NMR. Inorg. Chem. 1983, 22, 2958-2959.
11. Lempers, E. L. M.; Reedijk, J. Interactions of platinum amine compounds with sulfur-containing biomolecules and DNA fragments. Adv. Inorg. Chem. 1991, 37, 175-217.
12. Mirabelli, C. K.; Sung, C.-M.; Zimmerman, J. P.; Hill, D. T.; Mong, S.; Crooke, S. T. Interactions of gold coordination complexes with DNA. Biochem. Pharmacol. 1986, 35, 1427-1433.
13. Mirabelli, C. K.; Zimmerman, J. P.; Bartus, H. R.; Sung, C.-M.; Crooke, S. T. Inter-strand cross-links and single strand breaks produced by gold(I) and gold(III) coordination complexes. Biochem. Pharmacol. 1986, 35, 1435-1443.
14. Vicente, J.; Chicote, M. T.; Bermudez, M. D. 2-[(Dimethylammo)-methyl]phenylgold(III) complexes. J. Organomet. Chem. 1984, 268, 191-195.
15. Parish, R. V.; Howe, B. P.; Wright, J. P.; Mack, J.; Pritchard, R. G.; Buckley, R. G.; Elsome, A. M.; Fricker, S. P. Chemical and biological studies of dichloro(2-((dimethylamino)methyl)phenyl)-gold(III). Inorg. Chem. 1996, 35, 1659-1666.
16. Cleare, M. J.; Hydes, P. C.; Malerbi, B. W.; Watkins, D. M. Antitumour platinum complexes: relationships between chemical properties and activity. Biochimie 1918, 60, 835-850.
17. 2(dmamp)]. J. Chem. Soc., Dalton Trans. 1996, 69-74.
18. Kelland, L. R.; Barnard, C. F. J.; Evans, I. G.; Murrer, B. A.; Theobald, B. R. C.; Wyer, S. B.; Goddard, P. M.; Jones, M.; Valenti, M.; Bryant, A.; Rogers, P. M.; Harrap, K. R. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J. Med. Chem. 1995, 38, 3016-3024.
19. Mong, S.; Strong, J. E.; Bush, J. A.; Crooke, S. T. Use of covalently closed circular deoxyribonucleic acid for prescreening for antitumour compounds. Antimicrob. Agents Chemother. 1979, 16, 398-405.
20. Kohn, K. W.; Ewig, R. A. G.; Erickson, L. C.; Zwelling, L. A. Measurement of strand breaks and cross-links by alkaline elution. In DNA Repair : A Laboratory Manual of Research Procedures; Friedberg, E. C., Hanawalt, P. C., Eds.; Marcel Dekker: New York, 1981; Vol. 1, Part B, pp 379-401.
21. Schurig, J. E.; Meinema, H. A.; Timmer, K.; Long, B. H.; Casazza, A. M. Antitumor activity of bis[bis(diphenylphosphino)-alkane and alkene] group VIII metal complexes. Prog. Clin. Biochem. 1989, 10, 205-216.
22. Corbett, T. H.; Valeriote, F. A.; Baker, L. H. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest. New Drugs 1987, 5, 3-20.
23. Schwartsmann, G.; Workman, P. Anticancer drug screening and discovery in the 1990s: a European perspective. Eur. J. Cancer 1993, 29A, 3-14.
24. Fricker, S. P. Screening for new metal anti-tumour agents. In Metal Ions in Biology and Medicine; Collery, Ph., Poirier, L. A., Manfait, M., Etienne, J.-C., Eds.; John Libbey Eurotext: Paris, 1990; pp 452-456.
25. Hills, C. A.; Kelland, L. R.; Abel, G.; Siracky, J.; Wilson, A. P.; Harrap, K. R. Biological properties of a panel of ten human ovarian carcinoma cell lines: calibration against 4 platinum complexes. Br. J. Cancer 1989, 59, 527-534.
26. O'Neill, C. F.; Orr, R. M.; Kelland, L. R.; Harrap, K. R. Comparison of platinum (Pt) binding to DNA, and removal of total Pt adducts and interstrand crosslinks in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Cell. Pharmacol. 1995, 2, 1-7.
27. Johnson, S. W.; Perez, H. P.; Godwin, A. K.; Yeung, A. T.; Handel, L. M.; Ozols, R. F.; Hamilton, T. C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochem. Pharmacol. 1994, 47, 689-697.
28. Kelland, L. R.; Barnard, C. F. J.; Mellish, K. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Bryant, A.; Murrer, B. A.; Harrap, K. R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 1994, 54, 5618-5622.
29. Kelland, L. R.; Jones, M.; Abel, G.; Valenti, M.; Gwynne, J.; Harrap, K. R. Human ovarian carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery. Cancer Chemother. Pharmacol. 1992, 30, 43-50.
30. Comess, K. M.; Lippard, S. J. Molecular aspects of platinum-DNA interactions. In Molecular aspects of anticancer drug-DNA Interactions; Neidle, S., Waring, M., Eds.; Macmillan Press: London, 1993; Vol. 1, pp 134-168.
31. Goddard, P. M.; Valenti, M. R.; Harrap, K. R. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note. Ann. Oncol. 1991, 2, 535-540.
32. 2NCHMe-ring substituents. J. Organomet. Chem. 1981, 212, 283-290.
33. Leibovitz, A.; Stinson, J. C.; McCombs, W. B., III; McCoy, C. E.; Mazur, K. C.; Mabry, N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res. 1976, 36, 4562-4569.
34. Fogh, J.; Trempe, G. New human cell lines. In Human Tumour Cells in Vitro; Fogh, J., Ed.; Plenum Press: New York, 1975; pp 115-154.
35. Engel, L. W.; Young, N. A.; Tralka, T. S.; Lippman, M. E.; O'Brien, S. J.; Joyce, M. J. Establishment and characterization of three new continuous cell lines derived from human breast carcinomas. Cancer Res. 1978, 38, 3352-3364.
36. Rasheed, S.; Gardner, M. B.; Rongey, R. W.; Nelson-Rees, W. A.; Arnstein, P. Human bladder carcinoma: characterization of two new tumour cell lines and search for tumour viruses. J. Natl. Cancer Inst. 1977, 58, 881-890.
37. Fogh, J., Wright, W. C.; Loveless, J. D. Absence of HeLa cell contamination in 169 cell lines derived from human tumours. J. Natl. Cancer Inst. 1977, 58, 209-214.
38. Higgins, J. D., III; Neely, L.; Flicker, S. P. Synthesis and cytotoxicity of some cyclometallated palladium complexes. J. Inorg. Biochem. 1993, 49, 149-156.
39. Kelland, L. R.; Abel, G.; McKeage, M. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Murrer, B. A.; Harrap, K. R. Preclinical antitumour evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res. 1993, 53, 2581-2586.
40. Sealey, P. G.; Southern, E. M. Gel Electrophoresis of DNA. In Gel Electrophoresis of Nucleic Acids. A Practical Approach, 2nd ed.; Rickwood, D., Hames, B. D., Eds.; IRL Press: Oxford, 1990; pp 51-100.
41. Kelland, L. R.; Barnard, C. F. J.; Mellish, K. J.; Jones, M.; Goddard, P. M.; Valenti, M.; Bryant, A.; Murrer, B. A.; Harrap, K. R. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity. Cancer Res. 1994, 54, 5618-5622.
42. Ormerod, M. G.; Orr, R. M.; Peacock, J. H. The role of apoptosis in cell killing by cisplatin: a flow cytometric study. Br. J. Cancer 1994, 69, 93-100.